Percheron Therapeutics Limited (ASX:PER)
Australia flag Australia · Delayed Price · Currency is AUD
0.0070
0.00 (0.00%)
Mar 4, 2026, 2:06 PM AEST

Percheron Therapeutics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Revenue
---1.96--
Other Revenue
1.741.82.97-1.780.58
1.741.82.971.961.780.58
Revenue Growth (YoY)
-9.49%-39.32%51.07%10.51%207.72%-13.56%
Cost of Revenue
0.190.170.060.030.070.11
Gross Profit
1.551.632.911.931.710.47
Selling, General & Admin
3.654.153.842.842.82.18
Research & Development
5.9610.7710.710.164.544.91
Operating Expenses
11.0316.5414.8213.317.558.57
Operating Income
-9.48-14.91-11.92-11.38-5.83-8.11
Interest Expense
-0.01-0.01-0-0.01-0.01-0.01
Interest & Investment Income
----0.030
Currency Exchange Gain (Loss)
---0.01-0-0
EBT Excluding Unusual Items
-9.49-14.92-11.92-11.38-5.81-8.12
Other Unusual Items
-----0.05
Pretax Income
-9.49-14.92-11.92-11.38-5.81-8.06
Net Income
-9.49-14.92-11.92-11.38-5.81-8.06
Net Income to Common
-9.49-14.92-11.92-11.38-5.81-8.06
Shares Outstanding (Basic)
1,1041,024881669634541
Shares Outstanding (Diluted)
1,1041,024881669634541
Shares Change (YoY)
12.30%16.22%31.74%5.45%17.25%18.68%
EPS (Basic)
-0.01-0.01-0.01-0.02-0.01-0.01
EPS (Diluted)
-0.01-0.01-0.01-0.02-0.01-0.01
Free Cash Flow
-9.78-15.65-10.12-8.18-7.81-5.84
Free Cash Flow Per Share
-0.01-0.01-0.01-0.01-0.01-0.01
Gross Margin
89.17%90.71%97.91%98.32%96.31%80.91%
Operating Margin
-545.40%-827.68%-401.45%-579.21%-328.10%-1402.91%
Profit Margin
-546.23%-828.51%-401.57%-579.19%-326.89%-1395.14%
Free Cash Flow Margin
-562.85%-868.97%-340.93%-416.36%-439.23%-1011.23%
EBITDA
-9.43-14.84-11.84-11.37-5.83-8.1
D&A For EBITDA
0.050.070.080.010.010.01
EBIT
-9.48-14.91-11.92-11.38-5.83-8.11
Revenue as Reported
----1.810.64
Source: S&P Global Market Intelligence. Standard template. Financial Sources.